Compare Stocks: ZURA, STOK, AUPH, and ZBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$15.47 +1.9%	$15.91	$10.34 ▼ $19.25	$2.02B	1.42	1.14 million shs	826,711 shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.69	$16.90 ▼ $40.22	$2.02B	1.2	812,414 shs	495,115 shs
ZBIO Zenas BioPharma	$29.51 +1.1%	$26.95	$13.50 ▼ $44.60	$1.84B	-1.03	707,329 shs	630,044 shs
ZURA Zura Bio	$5.57 -1.1%	$4.99	$1.64 ▼ $7.44	$534.18M	-0.02	698,267 shs	794,583 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+1.91%	-2.40%	-3.91%	+1.24%	+28.81%
STOK Stoke Therapeutics	-0.13%	-4.40%	+4.55%	+3.96%	+84.92%
ZBIO Zenas BioPharma	+1.06%	-9.00%	+0.34%	+60.91%	+76.60%
ZURA Zura Bio	-1.07%	-6.70%	+3.34%	+18.01%	+250.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$15.47 +1.9%	$15.91	$10.34 ▼ $19.25	$2.02B	1.42	1.14 million shs	826,711 shs
STOK Stoke Therapeutics	$31.27 -0.1%	$30.69	$16.90 ▼ $40.22	$2.02B	1.2	812,414 shs	495,115 shs
ZBIO Zenas BioPharma	$29.51 +1.1%	$26.95	$13.50 ▼ $44.60	$1.84B	-1.03	707,329 shs	630,044 shs
ZURA Zura Bio	$5.57 -1.1%	$4.99	$1.64 ▼ $7.44	$534.18M	-0.02	698,267 shs	794,583 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+1.91%	-2.40%	-3.91%	+1.24%	+28.81%
STOK Stoke Therapeutics	-0.13%	-4.40%	+4.55%	+3.96%	+84.92%
ZBIO Zenas BioPharma	+1.06%	-9.00%	+0.34%	+60.91%	+76.60%
ZURA Zura Bio	-1.07%	-6.70%	+3.34%	+18.01%	+250.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.17	Hold	$17.67	14.20% Upside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	37.51% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$45.71	54.91% Upside
ZURA Zura Bio	2.75	Moderate Buy	$14.00	151.35% Upside

Current Analyst Ratings Breakdown

Latest ZURA, STOK, AUPH, and ZBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $32.00
8/14/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
8/14/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/12/2026	ZURA Zura Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $22.00
8/12/2026	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/4/2026	STOK Stoke Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/4/2026	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$38.00 ➝ $40.00
8/4/2026	STOK Stoke Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $58.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$283.05M	7.27	$1.03 per share	14.98	$4.62 per share	3.35
STOK Stoke Therapeutics	$27.59M	73.14	N/A	N/A	$5.36 per share	5.83
ZBIO Zenas BioPharma	$10M	186.30	N/A	N/A	$4.51 per share	6.54
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	6.76	17.99	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-121.14%	-64.55%	N/A
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	N/A

Latest ZURA, STOK, AUPH, and ZBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million
6/30/2026	Q2 2026	ZURA Zura Bio	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
STOK Stoke Therapeutics	N/A	7.69	7.69
ZBIO Zenas BioPharma	1.04	11.94	11.94
ZURA Zura Bio	N/A	12.90	19.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
STOK Stoke Therapeutics	N/A
ZBIO Zenas BioPharma	N/A
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	10.40%
STOK Stoke Therapeutics	9.60%
ZBIO Zenas BioPharma	22.00%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable
ZBIO Zenas BioPharma	N/A	63.13 million	49.24 million	N/A
ZURA Zura Bio	3	94.88 million	83.14 million	Optionable

ZURA, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

Zura Bio (NASDAQ:ZURA) Announces Quarterly Earnings Results

August 11, 2026 | marketbeat.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio (ZURA) Projected to Release Quarterly Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Zura Bio (ZURA) Projected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Stempoint Capital LP Makes New Investment in Zura Bio Limited $ZURA

July 30, 2026 | marketbeat.com

1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC

July 28, 2026 | marketbeat.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.8% - Still a Buy?

July 27, 2026 | marketbeat.com

Commodore Capital LP Invests $19.34 Million in Zura Bio Limited $ZURA

July 27, 2026 | marketbeat.com

Zura Bio Limited $ZURA Shares Acquired by Affinity Asset Advisors LLC

July 25, 2026 | marketbeat.com

Siren L.L.C. Acquires 2,434,866 Shares of Zura Bio Limited $ZURA

July 24, 2026 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

July 23, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Stock Price Up 5.3% - Time to Buy?

July 17, 2026 | marketbeat.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$15.47 +0.29 (+1.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$15.25 -0.22 (-1.42%)

As of 08/14/2026 07:34 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Stoke Therapeutics NASDAQ:STOK

$31.27 -0.04 (-0.13%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$31.28 +0.02 (+0.05%)

As of 08/14/2026 07:34 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$29.51 +0.31 (+1.06%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$29.50 -0.01 (-0.03%)

As of 08/14/2026 07:34 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zura Bio NASDAQ:ZURA

$5.57 -0.06 (-1.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.69 +0.12 (+2.14%)

As of 08/14/2026 07:34 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, STOK, AUPH, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, STOK, AUPH, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZURA, STOK, AUPH, and ZBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZURA, STOK, AUPH, and ZBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZURA, STOK, AUPH, and ZBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA, STOK, AUPH, and ZBIO Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

Stoke Therapeutics NASDAQ:STOK

Zenas BioPharma NASDAQ:ZBIO

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools